If you’re really care about translation of stem cell research into the clinic, you should watch this talk. The notable event of this year was the reports of the first encouraging results of use cardiac stem/progenitor cells in humans. One of the trials is ongoing in Cedars-Sinai Heart Institute.
Eduardo Marban – Professor, Director of the Cedars-Sinai Heart Institute. This year he reported results of CADUCEUS trial (cardiosphere-derived cells in myocardial infarction) in American Heart Association Meeting.
About bone marrow-derived cardiac cell therapy trials:
But uniformly in all studies that actually looked by state-of-the-art methods for evidence of regression of scar or regrowth of healthy tissue, it has not happened.
About CADUCEUS trial:
First therapeutic modality to shrink scar while regrowing viable, functional tissue.
Proof of concept in humans that cell therapy can achieve regeneration.
From Q&A:
In head-to-head comparison study, cardiosphere-derived cells were superior to bone marrow-derived mesenchymal stem cells.
The “Mesoblast” data were interested because they were completely negative, except for some clinical outcomes. What I’m worry about that so-called control and treatment groups were not properly randomized.
via @CIRMnews
PS: “A look inside of stem cell trial” is a new series of talks/ lectures on SCA. Check it out!
Related posts:
